冠状动脉支架内再狭窄:JACC最新综述
药物洗脱支架技术显著改善了经皮冠状动脉介入治疗的有效性和安全性,但支架内再狭窄(ISR)及由此导致的再次血运重建仍需每年1%-2%。鉴于全球每年植入数百万枚药物洗脱支架,ISR已成为具有公共卫生意义的病理实体。本文综述了ISR的发生率、机制和影像学特征,并提出了当代治疗算法,推荐使用冠状动脉内成像指导个体化治疗。
要点
- 药物洗脱支架时代ISR发生率仍为每年1%-2%,需再次血运重建。
- ISR机制是多因素的,冠状动脉内成像有助于阐明机制和模式。
- 推荐使用冠状动脉内成像表征ISR基质,指导个体化治疗。
核心结论
- ISR在药物洗脱支架时代仍是具有公共卫生意义的病理实体,推荐基于冠状动脉内成像的个体化治疗策略。
研究设计与样本
- 本文为JACC最先进综述,全面回顾了ISR的发生率、机制、成像特征及治疗策略。
主要发现
- 药物洗脱支架技术显著改善了PCI的有效性和安全性,但ISR及再次血运重建仍以每年1%-2%的速度发生。
- 全球每年植入数百万枚药物洗脱支架,ISR机制是多因素的。
- 冠状动脉内成像的出现进一步阐明了ISR的机制和模式。
- ISR的治疗策略和手段随时间演变。
关键数值与推荐
- 目前推荐使用冠状动脉内成像来表征ISR的 underlying substrate,以指导个体化治疗。
临床怎么用
- 临床中应使用冠状动脉内成像评估ISR的机制和模式,以制定个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction and subsequent iterations of drug-eluting stent technologies have substantially improved the efficacy and safety of percutaneous coronary interventions. However, the incidence of in-stent restenosis (ISR) and the resultant need for repeated revascularization still occur at a rate of 1%-2% per year. Given that millions of drug-eluting stents are implanted each year around the globe, ISR can be considered as a pathologic entity of public health significance. The mechanisms of ISR are multifactorial. Since the first description of the angiographic patterns of ISR, the advent of intracoronary imaging has further elucidated the mechanisms and patterns of ISR. The armamentarium and treatment strategies of ISR have also evolved over time. Currently, an individualized approach using intracoronary imaging to characterize the underlying substrate of ISR is recommended. In this paper, we comprehensively reviewed the incidence, mechanisms, and imaging characterization of ISR and propose a contemporary treatment algorithm.
引用
- Giustino G, Colombo A, Camaj A, et al. Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022. PMID: 35863852. doi:10.1016/j.jacc.2022.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。